1. Home
  2. DARE vs NYC Comparison

DARE vs NYC Comparison

Compare DARE & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DARE
  • NYC
  • Stock Information
  • Founded
  • DARE 2015
  • NYC 2013
  • Country
  • DARE United States
  • NYC United States
  • Employees
  • DARE N/A
  • NYC N/A
  • Industry
  • DARE Biotechnology: Pharmaceutical Preparations
  • NYC Real Estate
  • Sector
  • DARE Health Care
  • NYC Finance
  • Exchange
  • DARE Nasdaq
  • NYC Nasdaq
  • Market Cap
  • DARE 28.0M
  • NYC 25.5M
  • IPO Year
  • DARE N/A
  • NYC N/A
  • Fundamental
  • Price
  • DARE $2.10
  • NYC $9.60
  • Analyst Decision
  • DARE Strong Buy
  • NYC
  • Analyst Count
  • DARE 2
  • NYC 0
  • Target Price
  • DARE $10.00
  • NYC N/A
  • AVG Volume (30 Days)
  • DARE 124.8K
  • NYC 3.4K
  • Earning Date
  • DARE 11-13-2025
  • NYC 11-11-2025
  • Dividend Yield
  • DARE N/A
  • NYC N/A
  • EPS Growth
  • DARE N/A
  • NYC N/A
  • EPS
  • DARE N/A
  • NYC N/A
  • Revenue
  • DARE N/A
  • NYC $54,865,000.00
  • Revenue This Year
  • DARE $6,864.02
  • NYC $8.40
  • Revenue Next Year
  • DARE $4,922.46
  • NYC $1.62
  • P/E Ratio
  • DARE N/A
  • NYC N/A
  • Revenue Growth
  • DARE N/A
  • NYC N/A
  • 52 Week Low
  • DARE $1.83
  • NYC $7.89
  • 52 Week High
  • DARE $9.19
  • NYC $16.30
  • Technical
  • Relative Strength Index (RSI)
  • DARE 51.03
  • NYC 36.10
  • Support Level
  • DARE N/A
  • NYC $9.11
  • Resistance Level
  • DARE $2.15
  • NYC $10.50
  • Average True Range (ATR)
  • DARE 0.07
  • NYC 0.77
  • MACD
  • DARE -0.06
  • NYC -0.05
  • Stochastic Oscillator
  • DARE 95.53
  • NYC 22.98

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

About NYC American Strategic Investment Co.

American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.

Share on Social Networks: